hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
![hVIVO plc](https://directorstalk.net/wp-content/uploads/2022/11/hVIVO-plc-300x300.jpg)
hVIVO reports positive results from RSV antiviral human challenge trial with Shionogi
hVIVO plc, a leading CRO, collaborated with Shionogi for a successful Phase 2a RSV antiviral trial. Positive results show significant reduction in viral load.